Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first half

Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first half

Upworthy

Published

Moderna Inc. MRNA, said Thursday it had net income of $1.465 billion, or $3.61 a share, in the fourth quarter, down from $4.868 billion, or $11.29 a share, in the year-earlier period. Revenue fell to $5.084 billion from $7.211 billion a year ago. The FactSet consensus was for EPS of $4.60 and…

#modernaincmrna #eps #rsv #mercks #keytruda #spx

Full Article